Day 1 at #IMS2025 is in the books!
The MMRF team is on the ground in Toronto, bringing you insights from the world’s largest myeloma meeting. From new therapies to strategies for high-risk patients, see our recap of day 1:
👉 themmrf.org/mmrf-blogs/i...
Tecvayli is approved for later line therapies in relapsed/refractory patients. However, studies at #IMS2025 are highlighting the impact bispecifics like Tecvayli can have for newly diagnosed patients. Efficacy results are still very early, but encouraging.
Can we amend diagnostic criteria to help identify high risk smoldering patients? Dr. Sagar Lonial weighs in how circulating tumor cells could factor into these criteria #IMS2025
#IMS2025 kicks off with a promising stat—in 2025, there are currently 300+ myeloma papers published per month! This highlights the importance of the organizations like @theMMRF in expanding research efforts that increase options for #myeloma patients.
Blenrep has been approved in both the EU 🇪🇺 and Canada 🇨🇦—a meaningful step toward broader global access for myeloma patients.
In the U.S., the FDA review continues. Here’s what patients should know:
themmrf.org/mmrf-blogs/t...
#MultipleMyeloma #Blenrep #MMRF
The FDA has delayed its decision on Blenrep. The MMRF remains hopeful and continues to support approval. Blenrep offers real potential for patients who need accessible, effective care.
Learn more:
themmrf.org/mmrf-blogs/t...
#MultipleMyeloma #Blenrep #MMRF #FDA
The MMRF weighs in on the latest Blenrep (belantamab mafodotin) news and what it means for patients. With the FDA's decision pending, we’re closely watching next steps. Stay informed and read more 👉 themmrf.org/mmrf-blogs/t... #MultipleMyeloma #Blenrep
The FDA’s ODAC voted against the current benefit-risk profile of #Blenrep. Approval of this novel therapy is still pending.
The MMRF continues to champion safety, equitable access, shared decision-making & team-based care in the development of new #myeloma therapies.
▪️Beta 2-microglobulin (B2M): A protein found in the blood indicates the presence of myeloma
▪️Serum protein electrophoresis (SPEP): Used to detect the presence and levels of various proteins like M protein
▪️Complete blood count (CBC): the level of hemoglobin and the number of red blood cells, white blood cells, and platelets
▪️Chemistry profile (CMP): Measure levels of albumin, calcium, blood urea nitrogen (BUN), creatinine, and lactate dehydrogenase (LDH) in the blood
Having the right tests is important: they help your doctor confirm a diagnosis, assess the extent of your disease, & monitor progress once you start treatment. Download our Learn Your Labs booklet to better understand the blood tests used in myeloma care: themmrf.org/educational-...
⏰ URGENT: July 15 deadline approaching! #Myeloma patients are running out of options. The MMRF is the only organization solely dedicated to drug discovery and development for these patients. Your donation today will help extend lives. give.themmrf.org/campaign/687... #MMRF #CancerResearch
The FDA just approved a new #Elrexfio dosing schedule. Patients who achieve a sustained response after a set time can now dose every 4 weeks — a shift from the previous standard of biweekly dosing. This is a meaningful step toward reduced treatment burden in #MultipleMyeloma.
The MMRF's Dr. Chuck Acharya will present at the 3rd Annual IMS Workshop on Genomics:
📌 Mapping the interplay between tumor & immune microenvironment – insights from the Immune Atlas Consortium
📅 Jul 12, 9 AM (Lisbon, Portugal)
🔗 Register here: ow.ly/xJct50Wo2fC
Curious about the latest research in #myeloma treatment? Dr. @FaithEDavies1 & Dr. @OmarNadeemMD break down key updates from #ASCO25 and #EHA2025 during our Patient Livestream on 7/9 at 3pm ET. RSVP here: www.facebook.com/events/14846... #mmsm
@fda.gov approves bispecific antibody, Lynozyfic (linvoseltamab), for treatment of relapsed/refractory #myeloma patients who have received 4 prior lines of therapy.
investor.regeneron.com/news-release...
Learn more about LINKER-MM1 study. themmrf.org/mmrf-blogs/e...
🚨 Calling early-career researchers! The 2025 MMRF Scholars Program is now accepting applications. $400K over 4 years for rising stars in myeloma research.
🧬 Apply by 9/30.
🔗 ow.ly/uz4P50WjfTv
#theMMRF #Myeloma #ResearchFunding #CancerResearch
The FDA’s removal of REMS for CAR T therapy is a big step forward—improving access for #myeloma patients, especially in rural and underserved areas. It lowers barriers to care and expands access to next-generation CAR T therapies and treatment combinations. #HealthEquity
This past weekend, Dr. Chuck Acharya, Associate Director of Translational Research at the MMRF, presented at #EHA2025:
🧬 Immunomodulatory Effects of Daratumumab-Based Therapy in FHRMM Patients (MyDRUG Trial)
📅 June 14
📚 NEW CME/CE/CNE Activity for Healthcare Providers
In this free interactive activity, MMRF Chief Medical Officer Dr. Hearn Jay Cho summarizes key evidence on approved and emerging treatments for relapsed/refractory #myeloma. Claim your credit today: www.mycme.com/courses/trea...
TOMORROW: Don't miss our Patient Livestream! Dr. Cindy Varga, PA Jordan Robinson, and a #myeloma patient will answer your questions & share real-life experiences with bispecific antibodies. Set a reminder: www.facebook.com/events/10294... #mmsm
Feeling overwhelmed by your #myeloma journey? You're not alone. Whether you’re smoldering, newly diagnosed, or relapsed/refractory, our mentors are here to offer guidance & share real-life experiences. Connect with a mentor: themmrf.org/support/myel...
Wondering what bispecific antibody therapy is like? Join Dr. Cindy Varga, PA Jordan Robinson, & a #myeloma patient as they share real experiences & answer your questions.
📅 Live on Facebook!
👍 Mark "Interested" or "Going" on our event page: www.facebook.com/events/10294...
Day 2 at #ASCO25 delivered more promising updates for #myeloma patients including 5-year cancer-free results from CAR T-cell therapy, a potential new option with trispecific antibodies, a new way to give Sarclisa, and more.
Read all the highlights here: themmrf.org/mmrf-blogs/m...
Key takeaways are now available from Day 1 of the #ASCO25 Annual Meeting 🔬. Explore our latest blog to learn about promising updates on Blenrep, advances in treatment for newly diagnosed high-risk #myeloma patients, and more: themmrf.org/mmrf-blogs/m...
Can some of the limitations of bispecifics be overcome by introducing them in earlier lines of therapy? Dr. Attaya @suvannasankha weighs in on early data coming out of clinical trials testing bispecific combinations in newly diagnosed #myeloma patients. #ASCO2025
Dr. Evangelos Terpos discusses extending dose intervals with Belamaf to avoid ocular side effects while still preserving clinical response in older #myeloma patients. #ASCO25
New therapies discussed at #ASCO25, including a trispecific antibody tested in relapsed/refractory patients.
Continuing the MRD discussion at #ASCO25 — Drs. Ben Derman, Luciano Costa, Rebecca Silbermann, and Neha Korde share thoughts MRD based treatment decisions for patients and the future of integrating MRD across clinics.
📚 NEW CME/CE for HCPs
Relapsed/refractory #myeloma remains a treatment challenge, but new options like CAR T-cell therapy & bispecifics are shifting the landscape.
Learn from leading experts in this FREE accredited activity. Claim your credit today: ce.paradigmmc.com/a/BXWSSW